Neurological complications are a relevant cause of morbidity and mortality after haematopoietic stem cell transplantation (SCT). We retrospectively analysed neurological complications of 165 paediatric patients who underwent SCT between 1996 and 2003. In all, 111 (67%) transplantations were allogeneic and 54 (33%) transplantations were autologous. Post-SCT neurological complications were seen in 24% of patients. They were seen in six children after autologous SCT and in 11 and 23 cases after allogeneic-related and -unrelated SCT. Neurological symptoms occurred between day þ 22 and þ 912 after transplantation and were classified into two groups. The first group (n ¼ 21) offered non-repetitive symptoms lasting less than 24 h without any cerebral imaging and cerebrospinal fluid(CSF) abnormalities. The second group (n ¼ 19) was characterized by progressive neurological symptoms, pathological MRI findings and/or abnormal results in CSF. Those with a progressive clinical course resulted from infections (n ¼ 10), drug toxicity (n ¼ 5), cerebrovascular events (n ¼ 2) and the central nervous system (CNS) relapse of the underlying disease (n ¼ 2). In particular, cerebral aspergillosis and toxoplasmosis after allogeneic unrelated SCT are a major challenge and are associated with a high mortality. In conclusion, our data suggest that patients presenting with progressive neurological symptoms after SCT require prompt diagnostic procedures and initiation in antimicrobial therapy in case of any findings suggestive of CNS infection.
Introduction
Stem cell transplantation (SCT) is an effective therapeutic modality for a range of life-threatening diseases such as refractory haematological malignancies, lymphomas, solid tumours and non-malignant diseases. The long-term survival rates in children and adolescents have increased over the past 10 years and now approach 50%. 1 Central nervous system (CNS) complications are considered an important cause of morbidity and significantly contribute to mortality after SCT. [2] [3] [4] [5] Previous clinical studies reported neurological abnormalities in 11-59% of patients after SCT. 2, 3, 6 However, in autopsy studies neuropathological abnormalities were found in more than 90% of patients who died after SCT. In particular, cerebrovascular bleeding, fungal infection and toxoplasmosis were found as causes of death in these studies. 5 Mismatched related or unrelated donor allogeneic transplantation and the occurrence of GvHD were the most significant risk factors for development of neurological complications, most probably related to pronounced immunosuppression in such patients. [2] [3] [4] The wide range of incidence rate of neurological symptoms reported in the previous studies may be in part attributable to different classifications used, heterogeneous study populations, risk profiles and follow-up periods. Therefore, comparability among these studies is limited and very few data are available in the paediatric population.
In the present study, we therefore analysed incidence and aetiological factors of neurological complications after SCT and tried to identify transplantation-associated risk factors for their occurrence and outcome.
Patients and methods
Between January 1996 and December 2003, 165 primary SCTs and 23 secondary SCTs were performed at the bone marrow transplantation unit of the University Children's Hospital Du¨sseldorf.
Patient age ranged from three months to 30 years (mean age: 8 years and 11 months) and there was a clear male preponderance (111 male/54 female) in our study cohort. All patients X18 years (n ¼ 14) had previously been treated at our clinic for their underlying disease (n ¼ 7), or were referred to our department due to refractory Ewing Sarcoma (n ¼ 6) or for cord blood transplantation (n ¼ 1). 7, 8 High-dose chemotherapy with autologous stem cell rescue was performed in 54 patients, and 111 patients received allogeneic transplantation. Transplant characteristics of all patients are summarized in Table 1 .
Clinical management, preventative measures and diagnostic procedures All patients received antibacterial and antifungal prophylaxis from the day of admission and herpes simplex virus prophylaxis with acyclovir was started on day À8. Antifungal therapy was employed in case the fever persisted beyond three days of antibiotic treatment. 9 Prophylaxis for graft-versus-host disease (GvHD) in allogeneic transplant recipients included cyclosporine A (CsA) with or without methotrexate and/or antithymocyte globulin. CsA was given until day þ 100 and then tapered off. GvHD was diagnosed according to the Seattle criteria 10 and treated with increased doses of CsA and steroids. After 2002 mycophenolate mofetil was added in a few cases. None of the patients in this study received an in vitro T-cell depleted graft.
In 1998 and 1999 viral qualitative PCR screening for cytomegalovirus (CMV) and Epstein-Barr Virus was initiated and from 2000 on weekly quantitative PCR analysis of blood for CMV, Epstein-Barr Virus, human herpes virus 6, Parvovirus B19 and adenovirus was Table 1 Transplant characteristics of all patients (n ¼ 165) performed. A serum test for aspergillus infection using a galactomannan sandwich ELISA has been carried out weekly since the year 2000.
In the case of a seizure, the following investigations were routinely performed: whole blood count, electrolytes including magnesium level, C-reactive protein, blood gas analysis and ophthalmologic evaluation. In those cases where the ophthalmologic examination revealed uni-or bilateral papilloedema, lumbar puncture was performed to measure the CSF opening pressure. Cerebral imaging (MRI and/or CT) and examination of cerebrospinal fluid (CSF) were additionally undertaken between 1996 and 2003. The charts of all transplanted patients in our unit were retrospectively analysed with respect to the occurrence of one or more neurological symptoms, duration or relapse of clinical symptomatology and results of the diagnostic work-up. Patients were then classified as follows:
Group I
Transient, non-repetitive neurological symptoms present over a maximum of 24 h without MRI abnormalities and/or normal lumbar puncture.
Group II Symptoms persisting (424 h) or repetitive neurological symptoms associated with abnormal findings on cerebral imaging and/or abnormal results in CSF tests.
All neurological complications were further categorized according to the presumed aetiology based on the results of clinical examination, imaging studies and laboratory tests:
CNS infections (bacterial, viral, fungal, parasitic) Intracranial bleeding Metabolic disturbances (hypocalcaemia, hypomagnesaemia, hyper-or hypoglycaemia) Drug toxicity (CSA, FK 506, acyclovir) CNS involvement of underlying disease
Statistical methods
The data were descriptively analysed. Survival rates were estimated using the Kaplan-Meier method using the SPSS program version 12.0.
Results
Forty out of 165 patients (24%) developed one or more neurological symptom after SCT with a mean observation time of 42.5 months. Neurological CNS symptoms occurred between day þ 22 and day þ 912 after transplantation. Twenty-one out of 40 patients had a single episode with neurological symptoms (group I), while 19 had more than one episode over the course of therapy (group II).
Group I Two-third of patients of group I developed neurological complications during the first 100 days after transplantation. All except one patient underwent cerebral imaging, mostly MRI. No radiological abnormalities were found. CSF was investigated in 12 patients without abnormal cellular, chemical or microbiological findings. Two patients presented with papilloedema on routine eye examination. In these children, a lumbar puncture revealed a CSF opening pressure 425 cm H 2 O while CSF constituents were normal. MRI was normal in both patients leading to the diagnosis of pseudotumour cerebri or secondary intracranial hypertension. In nine patients, lumbar puncture was not performed based on normal cerebral imaging and rapid improvement of the clinical condition.
Group II
The characteristics of patients comprising group II are listed in Table 2 . Neurological complications in group II could be categorized into four main categories.
The first category included all intracranial infections (n ¼ 9) such as toxoplasmosis (cases 1-3), aspergillosis (cases 6 and 7) and viral infections with VZV (cases 4 and 5) or CMV (cases 8 and 9). The second category constitutes drug-induced neurotoxicity (n ¼ 4): CsA (case 12), FK 506 (case 13), acyclovir (cases 14 and 15) and manganese (case 16). The third category describes patients with cerebrovascular complications (cases 10 and 11). In addition, we have seen two patients with CNS relapse (cases 18 and 19) and one patient with encephalopathy of unknown aetiology (case 17).
In group II an association between the aetiology of the neurological complication and their occurrence time after transplantation could be discerned (Figure 1 ). Three time periods after transplantation could be distinguished with respect to aetiology (oday þ 100, oday þ 180, oday þ 365), each of them comprising a similar number of patients. Patients with neurological symptoms before day þ 100 had intracranial bleeding, drug toxicity due to Acyclovir and infections with toxoplasma or aspergillus. One patient with aspergillosis was seen almost one year after transplantation and was diagnosed by only cerebral imaging. CSF constituents were normal. Factors that contributed to infections were prolonged periods of neutropenia and immunosuppressive therapy. Patients with neurological symptoms between day þ 100 and þ 180 posttransplantation mostly had drug toxicity due to CsA or FK 506. Both patients had signs of GvHD III-IV and therefore, received prolonged immunosuppressive therapy. Neurological symptoms between day þ 180 and þ 365 were mainly attributable to viral infections or CNS relapse. All patients with CNS infections, except one with VZV after autologous transplantation, had prolonged immunosuppressive therapy for GvHD. After allogeneic SCT, 80% of the patients who developed neurological complications showed signs of GvHD.
Eighteen patients of group II underwent cerebral imaging. In 89% (n ¼ 16) MRI was performed, 11% (n ¼ 2) underwent cranial CT. Cerebral imaging revealed abnormal findings in all except two patients in group II (16 out of 18). CSF analysis was done on 13 patients in group II. This was conclusive in 69% of the cases (n ¼ 9) leading to the final diagnosis. In seven of these patients, the 
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C Weber et al suspected diagnosis of a CNS infection was confirmed (herpes virus n ¼ 4, toxoplasmosis n ¼ 2, aspergillosis n ¼ 1). In two patients CSF cytology confirmed a suspected CNS relapse. In four patients, CSF examination was considered normal. One of these was later diagnosed as suffering from cerebral toxoplasmosis which was confirmed by positive blood serology four weeks after two lumbar punctures were inconclusive. In two patients with normal CSF findings an aetiology other than an infection was found (CSA intoxication and cerebral bleeding). In one patient no cause for the neurological symptoms was found.
Outcome Twenty-two (55%) out of 40 patients with neurological complications died. Overall survival for all patients was 4475% over eight years. This corresponds to a 5-year overall survival of 4077% for autologous transplantation, 5977% for allogeneic-related transplantations and 4277% for allogeneic unrelated transplantations. In group II,11 (52.4%) out of 21 patients died due to their underlying disease or other non-neurological complications after transplantation. In group II, 11 (57.9%) out of 19 patients died. Seven of these (36.8%) died as a result of the neurological complication, one patient due to other complications related to the SCT and three patients due to underlying disease.
Discussion
The present study demonstrates that neurological CNS symptoms are a significant problem after SCT in the paediatric population at our institution. Between January 1996 and December 2003, 24% of children who underwent transplantation developed neurological complications. Neurological CNS symptoms occurred between day þ 22 and day þ 912, which clearly underlines the need for longer observation periods after SCT in clinical studies. The incidence of neurological CNS complications was highest in unrelated allogeneic transplantations (39%), followed by related allogeneic (21%) and autologous transplantations (11%). These findings are in accordance with previous clinical studies, which showed that neurological complications are seen more frequently in allogeneic, especially mismatched, transplantations 3, 4 particularly in patients with grade II-IV GvHD. 2 However, there is a marked variability of incidence rate among the different published studies, ranging from 11% in clinical series up to 90% in autopsy studies. Only a few studies were undertaken in the paediatric age group. Uckan et al.
2 found life-threatening neurological complications in 11 out of 113 children after BMT. A lower risk profile than in our study is indicated by the high proportion of HLA-matched-related transplantations, and higher proportion of patients with non-malignant conditions. In addition, the whole burden of CNS complications was probably underestimated due to a limited observation time of only three months post transplantation in that study. 2 In our study, we were able to identify a wide range of aetiological conditions. Five patients had an evidence of neurotoxic side effects of drugs used for GvHD prevention or treatment. Two of these children suffered from posterior reversible leukoencephalopathy syndrome associated with either CsA or FK 506. In both cases drug-associated posterior reversible leukoencephalopathy syndrome was reversible after reducing the dosage or withholding the drugs for a few days.
11
Many other drugs used as part of prophylactic or therapeutic regimes for opportunistic infections have the potential to cause encephalopathy. We have seen two patients with acyclovir intoxication. Discontinuation of the drug resulted in complete recovery in both cases. Acyclovir is known for its reversible neurotoxic side-effects, particularly in the presence of renal impairment. Diagnosis is made by high plasma levels in conjunction with the appropriate clinical condition and MRI images. 12 Intoxication of manganese as described in case 4 is an extremely rare condition after SCT. It may lead to severe encephalopathy. Manganese intoxication is mainly caused by hepatic dysfunction and long-term total parenteral nutrition. During total parenteral nutrition our children were provided with intravenous supplemental manganese, which, in the presence of hepatic dysfunction, lead to intoxication in our patient.
CNS infections have been reported as a cause of substantial morbidity and mortality in patients after SCT. 13 This is strongly supported by our data. A variety of causative infectious agents could be identified in our study. Neurological complications in paediatric patients after SCT C Weber et al Two patients with GvHD and prolonged neutropenia after allogeneic mismatched transplantation suffered from CNS aspergillosis. Both patients died within 14 days after diagnosis. Previous reports indicated that infections due to aspergillosis are major contributors to mortality of SCT patients. [14] [15] [16] Therefore, weekly controls for aspergillus antigen were introduced in the year 2000 at our institution. However, although both our patients had been screened, only one had positive aspergillus antigen later on during the course of the disease. Diagnosis was ultimately made by typical MRI findings. These findings confirm that early diagnosis of invasive aspergillosis in the immunocompromised patient remains a major challenge. PCR techniques are not well standardized and rarely lead to the ultimate diagnosis. Aspergillus serum antigen is characterized by high specificity but low sensitivity. Two positive results of aspergillus antigen or PCR are usually required to verify the diagnosis. 17 Moreover, although typical MRI findings have been described, appearance of cerebral lesions may be too late for successful treatment. Thus, the diagnosis of aspergillus infection is usually delayed.
In the current study three patients had toxoplasmic encephalitis, all diagnosed before day þ 100. Two of these had acute GvHD 4grade II. Initial CSF-PCR was positive in only one patient. In another case the CSF-PCR became positive several weeks after onset of the disease. All three patients died within two weeks after diagnosis.
Cerebral toxoplasmosis is considered a rare complication after SCT. In our experience cerebral toxoplasmosis is usually seen after engraftment in the early post transplantation period. The prognosis is poor with a mortality rate of up to 90%. 15, 16 Therefore, early diagnosis of this complication remains a major challenge. In order to achieve earlier diagnosis, it thus appears reasonable to check the serological status of all patients before SCT. 15, 18 Diagnostic difficulties and poor response to anti-infective treatment after onset of toxoplasma encephalitis would justify the use of medical prophylaxis after high-risk allogeneic SCT in seropositive recipients. 15 Viral infections, in particular infections with CMV, Herpes simplex and Epstein-Barr Virus have been described early after SCT. In the current study, two patients with CMV encephalitis were identified. One of these patients was transplanted in 1996 before introduction of weekly viral PCR screening at our institution. The other patient was transplanted in 1999. At this time regular screening for CMV by PCR had just been implemented at our clinic and positive CMV PCR results of this patient were only obtained after the CNS infection was already clinically manifest. Since introduction of regular PCRscreening and early antiviral therapy in patients who were tested positive, no further viral CNS infections have been observed.
Varicella zoster virus (VZV) as cause of late viral infections has also been described. 19 In our study we have seen two patients with late (4day þ 365) VZV infection. At this late period after SCT PCR screening and acyclovir (ACV) prophylaxis is not routinely performed at our clinic.
Signs of GvHD were seen in almost all our patients with neurological complications, particularly those of group II, thus representing an important risk factor for neurological complications in SCT patients. This may be in part attributable to the need for corticosteroids, FK506 and CsA as immunosuppressive treatment for GvHD, which may lead to a higher risk of CNS infections and druginduced toxic neurological effects. 15, [20] [21] [22] Two of our patients developed an early (days þ 22 and þ 28) and fatal intracranial haemorrhage. One of these patients had refractory thrombocytopenia and the other suffered from diffuse haemorrhagic diathesis of unknown aetiology.
In summary, in our study we were able to demonstrate that patients with neurological symptoms after SCT can be categorized into two groups with a distinct clinical outcome. The first group is characterized by transient, non-repetitive neurological symptoms presented over a maximum of 24 h without MRI abnormalities and/or normal lumbar puncture. While clinical manifestation usually occurred in the early post transplant period, aetiology remained unclear in all these patients. Most importantly, neurological outcome was generally good.
A second group consists of patients with persistent or repetitive neurological symptoms lasting more than 24 h with abnormal findings on cerebral imaging and/or CSF abnormalities. Summarizing the aetiological factors contributing to neurological complications in group II it appears that infections, drug toxicity and intracranial bleeding are the main causative conditions found (Figure 1 ). Our study indicates that CNS infections, in particular toxoplasmosis and aspergillosis, remain a major challenge due to unreliable methods for screening and early diagnosis and a high mortality. In general, neurological complications did not significantly contribute to the overall mortality rates, which were found to be similar in patients with or without neurological symptoms.
Clinical symptomatology observed in our population was highly unspecific. In most cases seizures, headache and altered level of consciousness were the presenting symptoms. However, as initial symptomatology does not allow for any prediction on the later clinical course, a comprehensive diagnostic work-up is recommended in any patient presenting with neurological symptoms. In our experience cerebral imaging and lumbar puncture had the greatest diagnostic value. As imaging studies often provide useful information only in advanced disease stages early presumptive treatment is clearly warranted in order to prevent fatal outcome particularly in CNS infections.
